Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
:SUPN
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.47Last Year’s EPS
0.77Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: 2.22%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
Supernus Pharmaceuticals demonstrated strong growth in core products Qelbree and GOCOVRI, introduced a promising new product ONAPGO, and maintained a solid cash position. However, these positives were offset by significant declines in legacy products and an increased operating loss, resulting in an overall net loss for the quarter.Company Guidance
During Supernus Pharmaceuticals' first quarter 2025 financial results conference call, guidance was reiterated for the full year, projecting total revenues to range from $600 million to $630 million, driven primarily by net product sales and royalty revenue. The company maintained its estimates for combined R&D and SG&A expenses to be between $435 million and $460 million. Non-GAAP operating earnings are expected to range from $105 million to $130 million, while GAAP operating earnings are projected to vary from a $15 million loss to a $10 million profit. The call highlighted a 26% increase in total revenues, excluding legacy products Trokendi XR and Oxtellar XR, due to the strong performance of Qelbree and GOCOVRI. Qelbree saw a 22% rise in prescriptions and a 44% jump in net sales, while GOCOVRI experienced a 12% increase in prescriptions and 16% growth in net sales. For the remainder of 2025, combined net sales of Trokendi XR and Oxtellar XR are expected to decrease, with guidance maintained at $65 million to $75 million. Supernus also launched ONAPGO, a subcutaneous apomorphine infusion device for Parkinson's disease, which received encouraging initial feedback from physicians.Double-Digit Revenue Growth
Total revenues, excluding Trokendi XR and Oxtellar XR, increased by 26% in the first quarter compared to the same quarter last year.
Qelbree Performance
Qelbree grew by 22% in prescriptions and by 44% in net sales. Monthly prescriptions in March reached an all-time high of 75,277, up 25% compared to the same period last year.
GOCOVRI Growth
Prescriptions for GOCOVRI increased by 12% and net sales increased by 16% compared to the same quarter last year, with Medicare prescriptions costing patients less than $25 for 84% of prescriptions.
Launch of ONAPGO
Launched ONAPGO, a new growth product for Parkinson's disease, with initial positive response from physicians and more than 75% of sales territories generating patient enrollment forms.
Strong Cash Position
The company had approximately $463.6 million in cash, cash equivalents, and marketable securities, maintaining a strong balance sheet.
SUPN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SUPN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $32.43 | $30.94 | -4.59% |
Feb 25, 2025 | $32.81 | $31.91 | -2.74% |
Nov 04, 2024 | $34.70 | $34.74 | +0.12% |
Aug 06, 2024 | $27.88 | $31.92 | +14.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Supernus Pharmaceuticals (SUPN) report earnings?
Supernus Pharmaceuticals (SUPN) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Supernus Pharmaceuticals (SUPN) earnings time?
Supernus Pharmaceuticals (SUPN) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SUPN EPS forecast?
SUPN EPS forecast for the fiscal quarter 2025 (Q2) is 0.47.